Simeon J. George, M.D.
Dr. Simeon George has served on our Board of Directors since April 2015. Dr. George joined SR One in 2007 and is CEO of the fund. He earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, recently acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded. We believe Dr. George’s experience in the biopharmaceutical industry, as well as his experience as a member on the boards of directors of multiple companies in the industry, qualifies him to serve on our Board of Directors.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.